Tangram Therapeutics

Today we announced a CEO transition at Tangram. Laura Roca-Alonso, who has served as COO/CBO since 2020, has been appointed Interim CEO, following Ali Mortazavi's decision to step down. Laura has played a central role in building Tangram over the past six years, and we’re excited for her to lead the team as we continue to advance our GalOmic pipeline and deliver key upcoming milestones. Find out more at link below 🔗

One step closer to bringing new medicines to patients. The first participant has been dosed in our Phase 1/2 RESTORE-MASH trial evaluating GalOmic RNAi medicine, TGM-312, in healthy volunteers and people living with MASH. Link below 🔗

LLibra OS’ flexible infrastructure underpins how we integrate evolving biology and advances in AI to discover differentiated RNAi medicines. Read the AWS case study on how we built and scaled LLibra OS to support the teams discovering and developing our GalOmic medicines. Link below 🔗

We’ve announced our first CTA submission, advancing TGM-312 for MASH into the clinic. Discovered in-house and backed by robust preclinical data, TGM-312 shows potential as a truly differentiated treatment option for people living with MASH. Find out more: tangramtx.com/press-release/…

Our GalOmic siRNA, TGM-312 for the treatment of MASH, has shown outstanding data in Gubra’s highly translatable GAN DIO-MASH model and is now advancing toward a CTA submission in Q4 2025. If you're at #TIDESEurope, attend our presentation to find out more.

Find out more here: tangramtx.com/press-release/… #RNAi #AI #Biotech #RelentlessMedicineDiscovery

e-therapeutics has relaunched as Tangram Therapeutics and simultaneously unveiled our next-generation AI platform LLibra OS. We're poised to unlock the true promise of RNAi medicines as we progress towards the clinic by the end of 2025.

We've announced significant progress on ETX-312, our lead GalOmic therapy for MASH: ✅ Positive non-clinical data with ETX-312 well tolerated across all dose levels ✅ On track for CTA submission in Q4 2025 Find out more here: etherapeutics.co.uk/news-and-media…

On Friday we presented our preclinical data on ETX-148 in haemophilia at @EAHADnews! It was a great opportunity to learn more about the latest advancements in the space and share our own data with the bleeding disorders community.

We are progressing towards the clinic! 🚀 Find out about our latest progress towards becoming a clinical-stage company and continued development of our HepNet platform in our business update and interim results, published today: etherapeutics.co.uk/news-and-media… #RNAi #AI #Biotech

We are looking forward to presenting new data from our GalOmic therapeutic pipeline at upcoming scientific conferences! Find out more here: etherapeutics.co.uk/news-and-media… #RNAi #siRNA #MASH #Cardiometabolic #Biotech #AI

Today, #ETX-sponsored Bodhana met with @RachelReevesMP at Downing Street as she prepares to represent England in the upcoming Chess Olympiad at just 9 years old. Good luck from everyone at ETX! #chess #biotech

We are extremely proud of #ETX-sponsored chess prodigy Bodhana who, at just 9 years old, will be the youngest person to represent England in an international sporting competition when she plays in the Chess Olympiad in September! theguardian.com/sport/article/… #biotech #chess #AI

We are pleased to announce our final results for the 2023/24 financial year, alongside some exciting pipeline updates! Find out more here: etherapeutics.co.uk/news-and-media… $ETX #RNAi #AI #Biotech

Just announced: Lord David Prior has joined as Chair of our Board of Directors! David's insights from his extensive healthcare experience will be invaluable as we progress our GalOmic™ therapies towards the clinic. Find out more: etherapeutics.co.uk/news-and-media… #RNAi #AI #Biotech

Just announced: We've raised £28.9m and are planning to delist from London’s #AIM. Proceeds from the fundraise will enable continued progression of our #RNAi assets towards the clinic and accelerated development of our #AI approaches! Find out more: londonstockexchange.com/news-article/E… $ETX #ETX #biotech